Plant & Quality
研究與發展Research & Development
High Barrier Generics
新聞發佈News & Media
/ Press Releases
TWi Pharmaceuticals announces the first shipment of its generic product in the U.S. market.
TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan.
TWi Pharmaceuticals announces that its Board has appointed Ms. Tina Guilder as the President & CEO and Ms. Eva Ho as CFO to enhance the strategic move to commercialize its products in the U.S. market.
TWi Pharmaceuticals announces that it will sell its products in the U.S. market, originally planned to be sold by Teva, through its wholly-owned subsidiary, TWi Pharmaceuticals USA
TWi Confirms Patent Challenge Relating to Oxtellar XR®, Oxcarbazepine ER Tablet
©Copyright 2013 安成國際藥業股份有限公司版權所有